论文部分内容阅读
目的:探讨地特胰岛素与门冬胰岛素治疗2型糖尿病的临床效果。方法:从东莞市第八人民医院2015年11月至2016年11月收治的2型糖尿病患者中,并且通过行C肽释放试验结果提示C肽基础水平较低,激发后升高达标,提示胰岛β细胞储备功能良好,随机抽取80例展开分组研究,即甲组40例,用门冬胰岛素30进行治疗;乙组40例,用地特胰岛素联合瑞格列奈治疗,对比两组的疗效及安全性。结果:治疗前两组的血糖水平比较国,差异无统计学意义(P>0.05,治疗后乙组优于甲组,差异具有统计学意义(P<0.05);乙组治疗总有效率高于甲组,差异具有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05),但甲组发生低血糖的几率略高于乙组。结论:与门冬胰岛素30相比,采取地特胰岛素联合瑞格列奈对2型糖尿病患者进行治疗,血糖水平恢复情况更佳,临床治疗效果更好。
Objective: To investigate the clinical effect of insulin detemir and aspart insulin in the treatment of type 2 diabetes mellitus. Methods: From Type II diabetes mellitus patients who were treated in Dongguan Eighth People’s Hospital from November 2015 to November 2016, and through the results of C-peptide release test, the basal level of C-peptide was low, and the basal level of C-peptide was raised after stimulation, suggesting that islets β cell reserve function well, 80 cases were randomly selected to start the study group, 40 cases of group A, with insulin aspart 30 for treatment; 40 cases of group B, with insulin and repaglinide insulin treatment, the two groups compared the efficacy and safety Sex. Results: There was no significant difference in blood glucose level between the two groups before treatment (P> 0.05, after treatment, group B was better than group A, the difference was statistically significant (P <0.05); The total effective rate of group B was higher than (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05), but the incidence of hypoglycemia in group A was slightly higher than that in group B. Conclusion: Compared with insulin aspart 30, gentamicin and repaglinide are used to treat patients with type 2 diabetes, blood glucose levels are better recovered, and clinical outcomes are better.